Summary
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
History
Founded in 2015, Travere Therapeutics is a privately held biopharmaceutical company focused on bringing life-changing therapies to the millions of people living with rare diseases. We are building a portfolio of treatments that are designed to address the unmet medical needs of our patients, their families and their caregivers. Our current pipeline includes treatments for rare metabolic and genetic diseases, an area of much needed attention from the medical community.
Mission
Our mission is to develop and deliver treatments that are life-changing for people living with rare diseases and their families.
Vision
Our vision is for a world where everyone affected by a rare disease can expect to receive the best possible care, through the development of therapies specifically designed to address their individual needs.
Key Team
Dr. Noah L. Rosenberg M.D. (Exec. Advisor)
Mr. Christopher Cline C.F.A., CFA (Chief Financial Officer)
Mr. Casey Logan (Sr. VP of Corp. & Bus. Devel.)
Ms. Sandra Calvin (VP, Corp. Controller & Principal Accounting Officer)
Ms. Charlotte Smith (Sr. VP of Public Affairs)
Ms. Angela Giannantonio (Sr. VP of HR)
Mr. Peter Heerma (Chief Commercial Officer)
Recognition and Awards
Travere Therapeutics has been recognized for its innovation by several industry sources, including the World Orphan Drug Awards, the FierceBioTech 15 Award and the Jay Pritzker Award for breakthrough research and development.
References
United States 